At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 24 enrolled

Drug / intervention

CD10367 3% Solution - Non-desquamated zone +5 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03025282

NCT03025282Phase 2Completed

Compare CT.gov

Exploratory Study to Evaluate the Safety and Efficacy of CD10367 in Subjects With Psoriasis

Galderma R&D·interventional·Posted Jan 19, 2017·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating CD10367 3% Solution - Non-desquamated zone, CD10367 1% Solution - Non-desquamated zone, and 4 other interventions for Psoriasis Vulgaris. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This was an exploratory, single-center, investigator blinded, randomized, controlled, intra-individual study, involving participants with psoriasis vulgaris. The objective was to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once daily application.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPsoriasis Vulgaris

CountriesFrance

Collaborators--

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

Enrollment StartNov 2016

First PostedJan 2017

Primary CompletionMar 2017

TodayJul 2026

First PostedJan 19, 2017

Enrollment StartNov 3, 2016

Primary CompletionMar 24, 2017

TodayJul 2, 2026

Enrollment to primary: 5 monthsPosted 9.5 years ago